keyword
MENU ▼
Read by QxMD icon Read
search

Pseudoprogression

keyword
https://www.readbyqxmd.com/read/29140135/pseudoprogression-on-bevacizumab-treatment-tumor-dynamics-in-the-modern-era-of-systemic-treatment-for-metastatic-colorectal-cancer
#1
Cornelis J A Punt, Joost Huiskens, Thomas van Gulik, Marc Engelbrecht
No abstract text is available yet for this article.
November 15, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/29131763/immune-checkpoint-inhibitor-cancer-therapy-spectrum-of-imaging-findings
#2
Gary X Wang, Vikram Kurra, Justin F Gainor, Ryan J Sullivan, Keith T Flaherty, Susanna I Lee, Florian J Fintelmann
Immune checkpoint inhibitors are a new class of cancer therapeutics that have demonstrated striking successes in a rapid series of clinical trials. Consequently, these drugs have dramatically increased in clinical use since being first approved for advanced melanoma in 2011. Current indications in addition to melanoma are non-small cell lung cancer, head and neck squamous cell carcinoma, renal cell carcinoma, urothelial carcinoma, and classical Hodgkin lymphoma. A small subset of patients treated with immune checkpoint inhibitors undergoes an atypical treatment response pattern termed pseudoprogression: New or enlarging lesions appear after initiation of therapy, thereby mimicking tumor progression, followed by an eventual decrease in total tumor burden...
November 2017: Radiographics: a Review Publication of the Radiological Society of North America, Inc
https://www.readbyqxmd.com/read/29118225/activity-of-entrectinib-in-a-patient-with-the-first-reported-ntrk-fusion-in-neuroendocrine-cancer
#3
Darren Sigal, Marie Tartar, Marin Xavier, Fei Bao, Patrick Foley, David Luo, Jason Christiansen, Zachary Hornby, Edna Chow Maneval, Pratik Multani
Despite advances in genomic analysis, the molecular origin of neuroendocrine tumors (NETs) is complex and poorly explained by described oncogenes. The neurotrophic TRK family, including NTRK1, 2, and 3, encode the proteins TRKA, TRKB, TRKC, respectively, involved in normal nerve development. Because NETs develop from the diffuse neuroendocrine system, we sought to determine whether NTRK alterations occur in NETs and whether TRK-targeted therapy would be effective. A patient with metastatic well-differentiated NET, likely of the small intestine, was enrolled on the STARTRK2 trial (ClinicalTrials...
November 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/29105360/pseudoprogression-as-an-adverse-event-of-glioblastoma-therapy
#4
Carmen Balaña, Jaume Capellades, Estela Pineda, Anna Estival, Josep Puig, Sira Domenech, Eugenia Verger, Teresa Pujol, Maria Martinez-García, Laura Oleaga, JoseMaria Velarde, Carlos Mesia, Rafael Fuentes, Jordi Marruecos, Sonia Del Barco, Salvador Villà, Cristina Carrato, Oscar Gallego, Miguel Gil-Gil, Jordi Craven-Bartle, Francesc Alameda
We explored predictive factors of pseudoprogression (PsP) and its impact on prognosis in a retrospective series of uniformly treated glioblastoma patients. Patients were classified as having PsP, early progression (eP) or neither (nP). We examined potential associations with clinical, molecular, and basal imaging characteristics and compared overall survival (OS), progression-free survival (PFS), post-progression survival (PPS) as well as the relationship between PFS and PPS in the three groups. Of the 256 patients studied, 56 (21...
November 3, 2017: Cancer Medicine
https://www.readbyqxmd.com/read/29104864/imaging-therapy-response-of-gastrointestinal-stromal-tumors-gist-with-fdg-pet-ct-and-mri-a-systematic-review
#5
REVIEW
Antonia Dimitrakopoulou-Strauss, Ulrich Ronellenfitsch, Caixia Cheng, Leyun Pan, Christos Sachpekidis, Peter Hohenberger, Thomas Henzler
Purpose: Improvement of the therapeutic approaches in gastrointestinal stromal tumors (GIST) by the introduction of targeted therapies requires appropriate diagnostic tools, which allow sufficient assessment of therapeutic response, including differentiation of true progression from pseudoprogression due to myxoid degeneration or intratumoral hemorrhage. In this literature review the impact and limitations of different imaging modalities used in GIST therapy monitoring are discussed. Methods: PubMed and Cochrane library search were performed using appropriate keywords...
2017: Clinical and Translational Imaging: Reviews in Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29103145/increased-signal-intensity-within-glioblastoma-resection-cavities-on-fluid-attenuated-inversion-recovery-imaging-to-detect-early-progressive-disease-in-patients-receiving-radiotherapy-with-concomitant-temozolomide-therapy
#6
Luke A Perry, Panagiotis Korfiatis, Jay P Agrawal, Bradley J Erickson
PURPOSE: Our study tested the diagnostic accuracy of increased signal intensity (SI) within FLAIR MR images of resection cavities in differentiating early progressive disease (ePD) from pseudoprogression (PsP) in patients with glioblastoma treated with radiotherapy with concomitant temozolomide therapy. METHODS: In this retrospective study approved by our Institutional Review Board, we evaluated the records of 122 consecutive patients with partially or totally resected glioblastoma...
November 4, 2017: Neuroradiology
https://www.readbyqxmd.com/read/29098766/some-statistical-considerations-in-the-clinical-development-of-cancer-immunotherapies
#7
Bo Huang
Immuno-oncology has emerged as an exciting new approach to cancer treatment. Common immunotherapy approaches include cancer vaccine, effector cell therapy, and T-cell-stimulating antibody. Checkpoint inhibitors such as cytotoxic T lymphocyte-associated antigen 4 and programmed death-1/L1 antagonists have shown promising results in multiple indications in solid tumors and hematology. However, the mechanisms of action of these novel drugs pose unique statistical challenges in the accurate evaluation of clinical safety and efficacy, including late-onset toxicity, dose optimization, evaluation of combination agents, pseudoprogression, and delayed and lasting clinical activity...
November 2, 2017: Pharmaceutical Statistics
https://www.readbyqxmd.com/read/29074633/comparison-between-the-prebolus-t1-measurement-and-the-fixed-t1-value-in-dynamic-contrast-enhanced-mr-imaging-for-the-differentiation-of-true-progression-from-pseudoprogression-in-glioblastoma-treated-with-concurrent-radiation-therapy-and-temozolomide-chemotherapy
#8
J G Nam, K M Kang, S H Choi, W H Lim, R-E Yoo, J-H Kim, T J Yun, C-H Sohn
BACKGROUND AND PURPOSE: Glioblastoma is the most common primary brain malignancy and differentiation of true progression from pseudoprogression is clinically important. Our purpose was to compare the diagnostic performance of dynamic contrast-enhanced pharmacokinetic parameters using the fixed T1 and measured T1 on differentiating true from pseudoprogression of glioblastoma after chemoradiation with temozolomide. MATERIALS AND METHODS: This retrospective study included 37 patients with histopathologically confirmed glioblastoma with new enhancing lesions after temozolomide chemoradiation defined as true progression (n = 15) or pseudoprogression (n = 22)...
October 26, 2017: AJNR. American Journal of Neuroradiology
https://www.readbyqxmd.com/read/29050959/sequential-proton-boost-after-standard-chemoradiation-for-high-grade-glioma
#9
Sebastian Adeberg, Denise Bernhardt, Semi Ben Harrabi, Matthias Uhl, Angela Paul, Nina Bougatf, Vivek Verma, Andreas Unterberg, Wolfgang Wick, Thomas Haberer, Stephanie E Combs, Klaus Herfarth, Juergen Debus, Stefan Rieken
PURPOSE: To retrospectively assess the feasibility and safety of a sequential proton boost following conventional chemoradiation in high-grade glioma (HGG). METHOD AND MATERIALS: Sixty-six consecutive patients with HGG were treated with 50.0 Gy photons (50.0-50.4 Gy) in 2.0 Gy (1.8-2.0 Gy) fractions, followed by a proton boost with 10 Gy equivalent (Gy(RBE)) in 2.0 Gy(RBE) fractions. Patients were matched one to one with 66 patients with HGG undergoing conventional radiation therapy (RT) with 60...
October 16, 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/29039692/imaging-spectrum-of-immunomodulating-chemotherapeutic-and-radiation-therapy-related-intracranial-effects
#10
Christie M Lincoln, Peter Fata, Susan Sotardi, Michael Pohlen, Tomas Uribe, Jacqueline A Bello
OBJECTIVE: A wide range of treatment-related side effects result in specific neurologic symptoms and signs and neuroimaging features. Even to the most seasoned neuroradiologist, elucidating therapy-related side effects from other common mimics can be challenging. We provide a pictorial survey of some common and uncommon medication-induced and therapy-related neuroimaging manifestations, discuss pathophysiology and common pitfalls in imaging and diagnosis. METHODS: A case-based review is utilized to depict scenarios on a routine basis in a general radiology or neuroradiology practice such as medication-induced posterior reversible encephalopathy syndrome to the more challenging cases of pseudoprogression and pseudoregression in temozolmide and bevacizumab therapy in gliobastoma treatment protocols...
November 3, 2017: British Journal of Radiology
https://www.readbyqxmd.com/read/29028766/immunotherapy-for-metastatic-urothelial-carcinoma-status-quo-and-the-future
#11
Andrea Necchi, Michael Rink, Patrizia Giannatempo, Daniele Raggi, Evanguelos Xylinas
PURPOSE OF REVIEW: The treatment paradigm of urothelial carcinoma has been revolutionized by the advent of multiple anti-programmed-cell death-1/ligand-1 (PD-1/PD-L1) antibodies. Significant improvements have been obtained in the locally advanced or metastatic stage, which was lacking of therapeutic standards. This review reports key findings from completed and ongoing clinical trials that highlight the potential of PD-1/PD-L1 blockade in this disease. RECENT FINDINGS: Anti-PD-1/PD-L1 monoclonal antibodies have shown efficacy and safety in patients with urothelial carcinoma, regardless of their prognostic features...
October 11, 2017: Current Opinion in Urology
https://www.readbyqxmd.com/read/29028584/diagnosis-and-treatment-options-for-sequelae-following-radiation-treatment-of-brain-tumors
#12
REVIEW
Swapnil Mehta, Aatman Shah, Henry Jung
Radiation serves an important role in the treatment of metastatic and primary brain tumors. Radiation carries a risk of post radiation treatment effects, such as pseudoprogression and radiation necrosis. The ability to differentiate between radiation necrosis, pseudoprogression, and tumor recurrence remains a diagnostic conundrum with varying treatment options. In this review, we will discuss the pathophysiology, diagnostic imaging modalities, and treatments of these post-radiation treatment effects. We focus on the latest developments in magnetic resonance imaging (MRI) modalities including imaging biomarkers and the newest therapeutics such as VEGF inhibitors, Hyperbaric Oxygen Therapy, sensitized cytotoxic T cells, and Laser Interstitial Thermal Therapy (LITT)...
December 2017: Clinical Neurology and Neurosurgery
https://www.readbyqxmd.com/read/29020535/treatment-of-glioblastoma
#13
Joo Yeon Nam, John F de Groot
Glioblastoma is the most common and most aggressive form of primary brain tumor in adults and contributes to high social and medical burden as a result of its incurable nature and significant neurologic morbidity. Despite ongoing research, there has not been improvement in survival in glioblastoma. This review discusses recent advances in clinically significant molecular profiling, including IDH mutation status and O(6)-methylguanine-DNA methyltransferase ( MGMT) promoter methylation. We review updates in management of newly diagnosed and recurrent glioblastoma, as well as common difficulties in management, such as pseudoprogression and pseudoresponse...
October 2017: Journal of Oncology Practice
https://www.readbyqxmd.com/read/28984142/visual-inspection-of-mr-relative-cerebral-blood-volume-maps-has-limited-value-for-distinguishing-progression-from-pseudoprogression-in-glioblastoma-multiforme-patients
#14
Melissa Kerkhof, Pauline L Tans, Rogier E Hagenbeek, Geert J Lycklama À Nijeholt, Finn K Holla, Tjeerd J Postma, Chiara S Straathof, Linda Dirven, Martin Jb Taphoorn, Maaike J Vos
AIM: We examined whether visual interpretation of relative cerebral blood volume (rCBV) color maps made with dynamic susceptibility-weighted perfusion MRI can reliably distinguish progressive disease (PD) from pseudoprogression (PsPD) in glioblastoma patients during treatment with temozolomide chemoradiation. MATERIALS & METHODS: Magnetic resonance (MR) perfusion-weighted images were evaluated based on visual inspection of rCBV maps. Sensitivity and specificity were calculated to assess if rCBV can reliably differentiate between PD and PsPD, during standard chemoradiation therapy...
October 6, 2017: CNS Oncology
https://www.readbyqxmd.com/read/28952228/differentiation-between-progression-and-pseudoprogresion-by-arterial-spin-labeling-mri-in-patients-with-glioblastoma-multiforme
#15
Marija Jovanovic, Sandra Radenkovic, Tatjana Stosic-Opincal, Slobodan Lavrnic, Svetlana Gavrilovic, Biljana Lazovic-Popovic, Ivan Soldatovic, Ruzica Maksimovic
PURPOSE: To compare arterial spin labeling (ASL) perfusion technique with the clinically established dynamic susceptibility contrast-enhanced (DSC) perfusion weighted-imaging (PWI), and to determine its value in routine MRI evaluation of disease progression in patients with glioblastoma multiforme (GBM). METHODS: A prospective intraindividual study was performed in 31 patients with histologically proven GBM who had clinical and/or radiological deterioration after treatment, including surgery, radiotherapy and therapy with temozolomide...
July 2017: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/28919393/pseudoprogression-associated-with-clinical-deterioration-and-worsening-quality-of-life-in-malignant-pleural-mesothelioma
#16
M B Barnet, R Zielinski, A Warby, C R Lewis, S Kao
No abstract text is available yet for this article.
September 12, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28915720/pseudoprogression-in-microsatellite-instability-high-colorectal-cancer-during-treatment-with-combination-t-cell-mediated-immunotherapy-a-case-report-and-literature-review
#17
Young Kwang Chae, Si Wang, Halla Nimeiri, Aparna Kalyan, Francis J Giles
Evading tumor-mediated immunosuppression through antibodies to immune checkpoints has shown clinical benefit in patients with select solid tumors. There is a heterogeneity of responses in patients receiving immunotherapy, including pseudoprogression in which the tumor burden increases initially before decreasing to reach disease control. The characteristics and basis of pseudoprogression, however, remains poorly understood. We hereby report a case of microsatellite instability (MSI)-high metastatic colorectal cancer treated with combination of OX40 agonist and programmed death ligand-1 (PD-L1) antagonist that demonstrated pseudoprogression reaching 163% increase from baseline tumor burden...
August 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/28874539/detection-of-immune-responses-after-immunotherapy-in-glioblastoma-using-pet-and-mri
#18
Joseph P Antonios, Horacio Soto, Richard G Everson, Diana L Moughon, Anthony C Wang, Joey Orpilla, Caius Radu, Benjamin M Ellingson, Jason T Lee, Timothy Cloughesy, Michael E Phelps, Johannes Czernin, Linda M Liau, Robert M Prins
Contrast-enhanced MRI is typically used to follow treatment response and progression in patients with glioblastoma (GBM). However, differentiating tumor progression from pseudoprogression remains a clinical dilemma largely unmitigated by current advances in imaging techniques. Noninvasive imaging techniques capable of distinguishing these two conditions could play an important role in the clinical management of patients with GBM and other brain malignancies. We hypothesized that PET probes for deoxycytidine kinase (dCK) could be used to differentiate immune inflammatory responses from other sources of contrast-enhancement on MRI...
September 19, 2017: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/28864727/immuno-oncology-clinical-trial-design-limitations-challenges-and-opportunities
#19
EDITORIAL
Christina S Baik, Eric H Rubin, Patrick M Forde, Janice M Mehnert, Deborah Collyar, Marcus O Butler, Erica L Dixon, Laura Q M Chow
Recent advances in immuno-oncology and regulatory approvals have been rapid and paradigm shifting in many difficult-to-treat malignancies. Despite immune checkpoint inhibitor therapy becoming the standard of care across multiple tumor types, there are many unanswered questions that need to be addressed before this therapeutic modality can be fully harnessed. Areas of limitations include treatment of patients not sufficiently represented in clinical trials, uncertainty of the optimal treatment dosing and duration, and lack of understanding regarding long-term immune related toxicities and atypical tumor responses...
September 1, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28862482/pseudoprogression-after-glioma-therapy-an-update
#20
Norbert Galldiks, Martin Kocher, Karl-Josef Langen
Initial diagnostics and follow-up of gliomas is usually based on contrast-enhanced MRI. However, the capacity of standard MRI to differentiate neoplastic tissue from posttherapeutic effects such as pseudoprogression is limited. Advanced neuroimaging methods may provide relevant additional information, which allow for a more accurate diagnosis especially in clinically equivocal situations. This review article focuses predominantly on PET using radiolabeled amino acids and advanced MRI techniques such as perfusion-weighted imaging (PWI) and summarizes the efforts of these methods regarding the identification of pseudoprogression after glioma therapy...
September 7, 2017: Expert Review of Neurotherapeutics
keyword
keyword
12545
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"